Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ㉥ 75 years: results of a real-world cohort including 456 patients

Gawaz, A.; Wolff, I.; Nanz, L.; Flatz, L.; Forschner, A.

dc.contributor.author	Gawaz, Andrea
dc.contributor.author	Wolff, Ines
dc.contributor.author	Nanz, Lena
dc.contributor.author	Flatz, Lukas
dc.contributor.author	Forschner, Andrea Lydia
dc.date.accessioned	2024-11-26T11:04:06Z
dc.date.available	2024-11-26T11:04:06Z
dc.date.issued	2024
dc.identifier.issn	0340-7004
dc.identifier.uri	http://hdl.handle.net/10900/159130
dc.language.iso	en	de_DE
dc.publisher	New York : Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s00262-024-03750-1	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ㉥ 75 years: results of a real-world cohort including 456 patients	de_DE
dc.type	Article	de_DE
utue.quellen.id	20241001000000_00830
utue.personen.roh	Gawaz, A.
utue.personen.roh	Wolff, I.
utue.personen.roh	Nanz, L.
utue.personen.roh	Flatz, L.
utue.personen.roh	Forschner, A.
dcterms.isPartOf.ZSTitelID	Cancer Immunology Immunotherapy	de_DE
dcterms.isPartOf.ZS-Issue	Article 185	de_DE
dcterms.isPartOf.ZS-Volume	73 (9)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE